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Summary We characterized a natural human anbbody to adenocarcinomas and investigated the biological role of this Ab/Ag complex in
cancer expansion. Human monoclonal antibodies (HuMAbs) were generated with hybridoma fusion methods using regional nodal
lymphocytes of colon carcinoma patients. Among 1036 HuMAbs, only one, termed SK1, an IgM, was adenocarcinoma specific in the
immunohistochemical study. The antigen recognized by SK1 (Ag-SK1) was a gtycoprotein with a molecular weight of 42-46 kDa. The
expression of Ag-SK1 on carcinoma cells varied according to the cell growth periods but was independent of cell cycle state as elucidated by
two-colour fluorescence-activated cell sorter (FACS) analysis. A dot-blot analysis showed that the concentration of Ag-SK1 per total protein
differed considerably among eight colon carcinoma cells examined and that the difference was closely correlated with the invasion capacity
of the cells as assessed by a microchemotaxis assay. Furthermore, up to 87% of cell migration was inhibited by SK1 in a dose-dependent
manner. These data suggested that Ag-SK1 is metabolized and expressed on highly invasive carcinoma cells. In addition, it appears that,
although rare, some patients do mount an anti-cancer antigen response in their draining lymph nodes. A HuMAb such as SK1 may be a good
candidate for the treatment of cancer invasion and metastasis.
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The draining lymph nodes of carcinoma tissues are exposed to
metastatic cancer cells. degradation products or materials secreted
by the main tumour vialymphangitic vessels. This suggests the exis-
tence ofan in situ immune response against tumour-associated anti-
gens. and. in fact. regional nodal lymphocytes have been a suitable
source offusion parents in producing tumour-reactive human mono-
clonal antibodies (Cole et al. 1984: Glassy. 1987: Kjeldsen et al.
1988: Inoue et al. 1989: Pfaff et al. 1990: Miyake et al. 1992). Both
practical and theoretical uses and limitations of using lymphocytes
isolated from regional draining, lymph nodes ofcancer patients have
been discussed (Glassy and McKnight. 1994: McKnight andGlassy.
1995). However. although insights into the human immune response
to cancer antigens have been obtained from these analyses. little is
known as to the physiological role of these auto-tumour-reactive
antibodies in carcinoma-bearing patients. The fact that cancers do
grow suggests that the antibody andlor other components that
normally function properly failed to do so.
In addition to the inhibition of cancer cell expansion. there is a
possibility that these antibodies may reduce cell-mediated cytotox-
icity by masking the target antigens for effector cells. Detenmining
this issue is essential when considering specific cancer biotherapy
using HuMAbs or cancer vaccines. In the current studv. we
characterized a human natural antibody to adenocarcinoma and
investigated the biological role of this Ag/Ab complex in cancer
expansion. In addition. we discussed the future potential of
immunotherapy using this human antibdy.
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MATERIALS AND METHODS
Cell lines
Carcinoma cell lines were all purchased from ATCC (Rockville.
MD. USA). A human lymphoblastoid cell line fusion partner.
sHFP-1. was grown and used as described previously (Glassy.
1989).
Hybridoma generation
Eighteen regional draining lymph nodes from six Dukes' B colon
carcinoma patients were taken aseptically from resected specimens.
Nodal lymphocvtes were prepared as a single-cell suspension by
mechanical dispersion with scalpels as described prexiously
(Glassy. 1987). Approximately 5.0 x 10 to 1.0 x 10- lymphocytes
from each lymph node were individually stimulated w-ith a cytokine
mixture (Borrebaeck et al. 1988) for 6-7 davs following an 'in vitro
stimulation' procedure (Koda and Glassy. 1990). This cvtokine
mixture was reported to contain a considerable amount of inter-
leukin (IL)-2 and interferon (fN)-gamma (Borrebaeck. 1987).
After stimulation. one part ofthe lymphocyies was mixed with tw o
parts of the human lymphoblastoid cell line sHFP- and washed
with serum-free RPMI-1640 three times. Ordinarv cell fusions
A-ere individually performed for each lymph node w-ith 50%c poly -
ethylene glycol 1500 (Boehrincer Mannheim. Germany-) as
described (Glassy et al. 1983). After the fusions. cells were resus-
pended in RPMI-1640 medium supplemented with 10% fetal calf
serum. glutamine and 0.2 nxLi hypoxanthine/0.2 JNiM amethopterinl
32 LiM thymidine (HAT: Sigma. St Louis. MO. USA) at S x I0
cells ml-'. Cells were then plated at 1.0 x lIW per vwell in 96vAell
microtitre plates without the use of feeder layer cells. Usually. 2-4
plates were prepared from one lymph node.
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EIA analysis
Approximately 2-5 weeks after the fusion. the wells were
screened microscopically for hybridoma growth. The supematants
ofwells showing positive hybridoma growth were first assayed for
producing human immunoglobulin by conventional ELISA, using
a 96-well assay plate precoated with goat anti-human IgM or
IgG (Jackson ImmunoResearch, West Grove. PA, USA). The
immunoreactive HuMAbs were then identified by cell-EIA on a
panel of cell lines immobilized on Falcon flexible assay plates
(Glassy and Surh. 1985). Briefly, logarithmic phase cells were
collected with 0.02% EDTA in calcium- and magnesium-free
Dulbecco-phosphate-buffered saline (PBS) (D-PBS). washed
twice in D-PBS, resuspended and aliquoted at 2 x 10- cells per
well of flat-bottom 96-well plates. These plates were then placed
overnight in a 37°C drying oven and then stored until use. After
blocking the plate with 0.5% bovine serum albumin (BSA)/D-
PBS, 50 ml oftest supernatants were added to the wells, incubated
for 1 h at room temperature. washed three times with 0.5% Tween
20/D-PBS and incubated for an additional 30 min with an affinity-
purified horseradish peroxidase (HRP)-conjugated goat anti-
human IgM (Jackson ImmunoResearch). Following washings.
plates were developed with orthophenylenediamine (OPD) plus
hydrogen peroxide in citrate buffer, pH 5.0. Reactions were
stopped with 2.5 M sulphuric acid solution, and were read at 492
nm with an enzyme immunoassay (EIA) reader. The positive
HuMAbs were subjected to immunostaining ofseveral human cell
lines to eliminate the false-positive clones inherent in cell ELAs
(Kodaetal. 1990).
Purification of HuMAb SKi
To stabilize a clone secreting a large amount of immunoglobulin.
the hybridoma secreting HuMAb SKI was cloned by four inde-
pendent series of limiting dilutions (one cell per well). The best
clone recovered secreted approximately 1.2-1.5 jg ml-' 1.0 x 106
24 h-' for at least 2 months in continuous culture and doubled in
quantity every 20-26 h. The hybridoma was cultured in serum-
free medium. S-Clone (Sanko Junyaku. Tokyo, Japan), and 101 of
culture supernatant was collected. Proteins were then precipitated
by the salting-out method using 45% saturated ammonium
sulphate. The precipitate was then dialysed thoroughly against
Ca+ and Mg2+ free D-PBS. The solution was then passed through
an affinity column in which goat anti-human IgM monoclonal
antibody was affixed to CNBr-Sepharose 4B (Pharmacia, Tokyo,
Japan) at 1 mg g' gel. After washing the column with Ca'+ and
Mg2+ free D-PBS, human IgM was eluted with 6 M guanidine
hydrochloride. The effluent was immediately dialysed against
D-PBS, and the concentration of human IgM was adjusted to
100 jig ml-'with D-PBS supplemented with 1% human albumin.
Antigen characterization
One half of the target cells immobilized on to assay plates were
treated with several enzymes to estimate the antigen nature recog-
nized by the HuMAbs. Periodate treatment was performed with
S mM periodic acid (Sigma) in sodium acetate buffer, pH 4.5,
at room temperature for 45 min. Neuraminidase (Sigma) was
diluted to 1 unit ml' with citrate phosphate buffer, pH 5.0, and
incubated with cells overnight at 370C. Trypsin at 0.1% concentra-
tion. pH 7.6. was incubated with cells at 37°C for 20 min. After
washing. ordinary cell EIA was perforned. and the alterations in
reactivity. ifany. were evaluated.
Invasion assay
The invasion capacity of colon carcinoma cell lines was deter-
mined using a 24-well microchemotaxis chamber (Kurashiki
Boseki, Okayama. Japan) in quadruplicate assay (Aznavoorian et
al, 1990). A polycarbonate membrane with an 8-jm pore size was
precoated with an extracellular matrix mixture in D-PBS
(40 jg ml-' of type 4 collagen. 10 jg ml-' fibronectin and
5 jg ml-' laminin. all from Cosmo Bio. Tokyo. Japan) by soaking
overnight in this mixture at 4°C. After removal of the solution.
RPMI-1640 supplemented with 10% fetal calf serum (FCS) was
added to the unit. In the upper chamber, I0W cells per well were
seeded, whereas, in the lower chamber, 5 jg ml-' laminin.
fibronectin and type 4 collagen were added as chemoattractants.
After 36 h of incubation at 37°C in a 5% carbon dioxide humidi-
fied incubator, the membranes were fixed with cold acetone for
8 min and stained with Meyer's haematoxylin. The number of
cells that migrated to the lower side of the membrane was micro-
scopically counted and evaluated. In some experiments either
purified HuMAb SKI or irrelevant human IgM MAb was added to
the upper chamber at various concentrations to inhibit the cell
migration with antibodies.
Immunohistochemical staining
A panel of frozen sections (4 jm thick) of human tissues was
stained with HuMAb SKI using a standard avidin-biotin peroxi-
dase complex (ABC) method. Whendeparaffinized formalin-fixed
sections were used, they were soaked in 0.1 M citrate buffer
(pH 6.0) and treated with microwaves twice for 10 min as
described previously (Shi et al, 1991; van den Berg et al. 1993).
Frozen sections were fixed with cold acetone for 8 min before the
blocking procedures. Sections were first treated with 0.03%
hydrogen peroxidase in methanol for 30 min, washed, then
blocked with 1% BSAID-PBS plus 5 jg ml' of goat anti-human
IgM (Jackson lmmunoResearch) at room temperature for 1 h.
Afterwashing withD-PBS, HuMAb SKI diluted to 5 jg ml-' with
0.5% BSA/D-PBS was applied and incubated overnight in the
moist chamber at 4°C. After washing. the sections were incubated
with biotinylated goat anti-human IgM (Jackson Immuno-
Research) for 1 h at room temperature. They were then washed
and incubated with avidin-biotinylated peroxidase complex (ABC
staining kit from Dako Japan. Tokyo, Japan) for I h at room
temperature. After several more washings, slides were reacted
with diaminobenzidine substrate for 10 min. rinsed, counter-
stained with haematoxylin and mounted.
Flow cytometry
Single cell suspensions ofcolon carcinoma cell lines were treated
with 3.7% formaldehyde solution for 10 min at room temperature.
After removal of the solution, cold acetone was added and incu-
bated on ice for 5 min. washed, then incubated in 5% FCS/D-PBS
for 1 h. Following washings. SKI or human polyclonal IgM (each
at 5 jg ml-'), was applied and incubated on a shaker for 1 h at
room temperature. washed. then appropriately diluted FITC-
conjugated goat anti-human IgM (Jackson ImmunoResearch) was
added and incubated for an additional 30 min at room temperature.
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After washina. they were passed through a nylon mesh (200 inch-'
mesh). stained with propidium iodide (PI: 20 jgc ml-'. Siama) and
then analysed with FACScan (Becton Dickinson Japan. Tokyo.
Japan). The signal from fluorescein isothiocyanate (FITC) corre-
sponding to Ag-SKI levels was measured with a 530-nm bandpass
filter. The PI signal corresponding to the DNA content was
measured with a 585-nm bandpass filter in conjunction with a 640-
nm longpass filter. The doublet GJG, phase cells that resemble
singlet G,/M phase cells were eliminated bv setting a gate on the
PI pulse intensity vs the PI pulse width blottingy field.
Dot-blot analysis
Cell lysates in 0.01 Im Tris-HCl (pH 7.2) and 0.15 mi sodium chlo-
ride (Tris buffered saline: TBS) were prepared from logarithmic
phase cells (3 davs after subculture) usincg an ultra-sonicator.
After centrifugiation at 3000g for 10 min. the supernatants were
collected and the total protein concentration was determined using
a Bio-Rad Protein Assay kit (Nippon Bio-Rad Laboratory. Tokyo.
Japan) following the standard procedure. The protein concentra-
tion was adjusted to 100 gg ml'. and serially diluted samples
were fixed on a nitrocellulose membrane using a Bio-Dot
Microfiltration Apparatus (Bio-Rad). The membrane was then air
dried and soaked in the blocking solution (50 mmni Tris. 2%r BSA.
0.25%c gelatin. 0.154 mi sodium chloride) for 3 h. The HuMAb SKI
at 5 o,g mll in 0.5% BSA/TBS was then added and incubated at
room temperature for 1 h. It was washed again and incubated with
HRP-conjugated goat anti-human 1gM (Jackson) for 30 min. After
washing. the reactivit; was visualized with a peroxidase substrate
kit (Bio-Rad)
SDS-PAGE and Western blot
Cell lysates prepared with an ultra sonicator were mixed w-ith a
sample buffer (final concentration: 0.06sm Tris-HCl. 2%/c SDS.
10% glycerol) and heated at 95 C for 4 min. Acrvlamide gel elec-
trophoresis was performed w-ith a Bio-Rad mini-Protean H slab gel
apparatus using precast 4-15c linear gradient gels (Bio-Rad)
under non-reducing conditions. Separated proteins Aere then
transferred onto a nitrocellulose membrane usinc a Bio-Rad mini
trans-blot apparatus. The blotted filters were stained with HuMAb
SKT as described above.
RESULTS
Colon carcinoma reactive antibody
A total of 1036 immunoglobulin-secreting hybridomas were
generated from the 18 lymph nodes obtained from six Dukes B
colon carcinoma patients. The cell EIA and the immunocytochem-
ical stainings revealed that 16 antibody-containincg supernatants
were reactive to colon carcinoma cells and such hvbridomas were
generated by each of the patients investigated. However. the
immunocytochemical stainings of a panel of cultured cell lines
with these antibodies showed that most of the selected HuMAbs
were not specific to carcinoma but were multi-reactive. even to
non-malignant cells (Koda et al. 1990). Among these HuMAbs.
SKI showed the most restricted specificity to carcinoma cell lines
(Chang, et al. 1993). This carcinoma-preferred reactivits Aas
confirmed by immunohistochemical study in which SKI reacted
mainly Awith malignant tissues originating in the epithelium
(Table 1: Figure 1). In many of the cases the obserxed immuno-
histochemical staining was heterogeneous. as clearly seen in
Figure lB and C.
Overall. 107 out of 109 colorectal cancer cases scored as A2-
SKl positive. as were 10 out of 11 stomach cancers and four out of
four pancreatic cancers (Table 1). Breast cancer scored positive in
fixve out ofeight cases. representing, approximately 62%7. Only one
case out of 30 normal colorectal mucosa tissues tested scored as
Ag-SKI positive. Weak or trace stainings were observed with liver
(Mtx o out of seven). pancreas (two out of four) and kidnev (one out
of four) tissues. All the rest were negative. The overall reactivity
pattern w-as clearly adenocarcinoma-restricted.
Partial Ag-SK1 analysis
The HuMAb SK1 lost most reactivitx to target cells treated w-ith
neuraminidase. trypsin orperiodate (data not shown). suggesting that
the antigen nature ofAg-SKI was a glycoprotein. The approximate
molecular weight of Ag-SKI was a two-chain structure of 42-
46 kDa. as seen by SDS-PAGE with non-reducincg conditions.
followed by Western blot (Figure 2). Normal colon mucosa ofulcer-
ative colitis and fibroblast cells were negative for this tmo-chain
structure whereas both primary colorectal carcinoma tissue and a
colorectal cancer that metastasized to the liver were Ag-SK1 positix e
(Figure 2).
Ag-SK1 expression on cancer cells
Analysis of colonies of HT-29 cells. a carcinoma of the colon.
indicated that Ag-SK1 expression w-as regulated by either cell
Table 1 Immunohistochemical staining of human tissues with HuMAb SK1
Number of tissues
Tissues Ag-SK1(+) Ag-SK1(trace) Ag-SK1(-)
Colorectal cancer 107 2 0
Colorectal mucosa 1 3 26
Stomach cancer 10 1 0
Stomach mucosa 0 0 11
Pancreatic cancer 4 0 0
Pancreas 0 2 2
Liver 0 2 5
Lung cancer 2 0 0
Lung 0 0 4
Kidney 0 1 4
Brain 0 0 4
Melanoma 0 0 6
Sarcoma 0 0 4
Breast cancer 5 0 3
Prostate 0 0 3
Skin 0 0 3
Oesophagus 0 0 3
Bladder 0 0 3
Testis 0 0 3
Ovary 0 0 3
Uterus 0 0 3
Spleen 0 0 3
Thyroid 0 0 3
Heart 0 0 3
Bone marrow 0 0 3
Eye 0 0 3
Nerve 0 0 4
Skeletal muscle 0 0 6
Salivary gland 0 0 1
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Figure 1 Immunohistochemical staining of colon carcinoma tissues with HuMAb SK1. Four examples (A-D) are shown. In many of the cases the observed
staining was heterogeneous, as dearty seen in B and C. Scale bar = 100 gm
proliferation or cell density. This is shown in Figure 3. Figure 3A
shows the degree on immunostaining by individual cells. and 3B
shows a small colony. The outerperipheral region. typically a three-
to five-cell-thick layer. ofa largercolony ofcells (Figure 3C and D)
shows good immunostaining. whereas the cells in the centre of the
colony are poorly. if at all. stained. The outer peripheral cells ofthe
colony are actively growing. mov'ing outward and therefore
expressing Ag-SKI. On the other hand. the inferior cells of the
colony are neither growing nor moving. and are Ag-SKI negative.
To further understand the proliferative nature of Ag-SKI. we
analysed the expression of the antigen on Calu-1 cells. a carci-
noma ofthe lung. each day as the culture expanded. These data are
shown in Figure 4. Calu-1 cells were seeded at low density (Figure
4. ID) and allowed to expand until the cultures were greater than
90% confluent. typically by days 6-7. As can be seen. the antigen
is diffuse and spread throughout the cell in very low-density
cultures. By day 3. the antigen has rounded up' and can be seen
indenting the nucleus. High-density cultures were Ag-SKl nega-
tive by immunostaining. Similar findings were also observed in
PANC-1. pancreatic cancer cells (data not shown). These data
suggest that Ag-SKl is not always expressed on a given carcinoma
cell but is metabolized in each cell depending on the circum-
stances. Two-colour FACS analysis using HuMAb SKI and PI
showed that antigen expression in each cell is independent of the
cell cycle status (Figure 5).
Dot-blot analysis
The amount of Ag-SKl per extracted cell protein was assessed by
dot-blot analysis (Figure 6. Table 2). where the ratio of Ag-SKI-
positive cells was deternined by FACS analysis (Table 2). We
showed that the concentration ofAg-SK1 perprotein differs consid-
erably among cell lines. in which SW620. WiDr and LoVo cell lines
were considered to express a high amount ofAg-SKL. with the low
expression group consisting of Caco-2 and NCI-H716 cell lines.
The data shown in Figure 6 were obtained from cells harvested
dunrng mid-log growth (between 30% and 50% confluent. usually
3-4 days' culture) when antigen expression was highest.
In FACS analysis. the antigen-positive cells within each cell line
were recorded as a discrete subset with more than ten times greater
antigen expression in comparison with the negative cells (Figure
SB). The ratio ofAg-SK1-positive cells in each cell line varied in
accordance with the harvested time of the cells. However. there
was a tendency for cells with high Ag-SK1 concentration in dot-
blot analysis to have higher antigen-positive ratios in FACS
analysis (Table 2).
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Figure3 Immunocytochemical staining ofcoiony-forming colon carcinoma cell line HT-29. All the cells in the small colony (A) were antigen-SK1 positive,
whereas in intermediate or large colonies (B, C), only cells that form the peripheral region of each colony were stained with HuMAb SK1. On a magnified view of
C (D), the intensity of staining differed considerably between inner and outer cells. Scale bar 50gm in figures A, B and D; 500gim in C
British Joumal ofCancer (1998) 78(10), 1313-1322
-ft .---
0 Cancer Research Campaign 1998:I
-r
r
,r
0.^
1D
4D 5D
Figure 4 Successive changes in antigen expression found in Calu-1 lung carcinoma cell line. On 1-7 days (1D-7D) after the beginning of subculture, cells
were stained with HuMAb SK1. A broadty expressed cytoplasmic antigen. which is seen on ID and 2D, was condensed beside nuclei on 3D (indicated by
arrows). The antgen was dispersed again on 40, and was hardly seen on 7D when cells become more than 90% confluent.Scale bars = 50 um
Table 2 Cell invasion capacity and concentration of Ag-SK1
Cell line Number of migrated Conentration of Ag-SKI positive
cells (mean ± s.d.) Ag-SK1 assessed by cells determined
dot-blot analysisb by FACSC (%)
SW620 232 52 32x >90
WiDr 155 ± 37 32x 40-70
LoVo 89 + 23 16x 60-0
LS174T 93 ± 21 8x 60-0
COLO320DM 72 + 15 8x 30-50
HT-29 22 ± 13 8x 4G0-
NCI-H716 <10 4x 30-50
Caco-2 <10 2x 20-40
aMid4Og phase cells(30-500o confluent) were harvested and prepared foranalysis. bData indicate maximum
dilution ratio of the extracted protein that can be detected by HuMAb SK1 on dot-blot analysis (see Materials and
methods). cThe positive ratio was calculated with Kokgomobov-Smimov statistics.
Invasion capacity of colon carcinoma cell lines
The cell invasion capacity was determined with a microchemo-
taxis assay. and the data are summarized in Table 2. The number of
cells that migrated to the lower chamber was high in SW620 and
WiDr cell lines. Ahereas almost no invaded cells were observed in
NCI-H716 and Caco-2 cells. When comparinc the cell invasion
capacitv. with the amount of Ag-SKI in each cell line. there w as a
tendency for the cell lines wA-ith high invasion capacity to has-e a
higher amount of Ag-SKl (Table 2).
To confirm the hypothesis that A-SKI was an invasion- or a
migration-related molecule of colon carcinomas. we next investi-
gated whether the invasion capacity of these cells was inhibited bv
the addition ofHuMAb SKl into the upper sides ofthe chemotaxis
chambers in a quadruplicate assay. As shown in Figure 7. only a
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FLgure 6 Dot-blot anaiysis for determiig the antigen concentraton in
colon carcma cel ines. Aliquots of 100 mg of extraced cell protein from
each cell line were dotted on Fe first colum. From te second column,
ser-y double-dkltd samples were dotted. The membran was then stained
with HuMAb SK1. Cel lines used were: 1, SW620; 2, WiDr; 3, LoVo; 4,
LS174T; 5, COLO320DM; 6, HT-29; 7, NC14-716; 8, Caco-2
101 icF ;
Figure 5 Cell cycle-ndependent expression of the anfigen on colon
carcinoma cell line, SW620. The verfica line indictes propidium iodide (PI)
signal in linear scale corresspon to DNA content of each cell, whereas the
horizorna line indicates log fluorescei isotiocyanate (FITC) signal obtired
from (A) human poWycorna IgM antlody, 5 9Ig ml-' and (B) HLuMAb SKi,
5 9g mlV. Ther was no correlaion between DNA content (cell cye) and the
number of Ag-SK1-positve cells
limited number of cells migrated to the lower side of the
membrane after 36 h ofincubation with HuMAb SKI. This inhibi-
tion was dose dependent and up to 87% of cell migration was
blocked with 1 gtg ml-IHuMAb Skl (Figure 8).
DISCUSSION
Data have been accumulating indicating that the overall immune
system of cancer-bearing patients is able to recognize autologous
tumour antigens specifically. In cellular immunity, the cytotoxic T
lymphocyte that specifically targets autologous tumours has been
induced in vitro (Barnd et al, 1989; Wright et al. 1989; Topalian et
al, 1989; Peoples et al, 1995). In humoral immunity, human mono-
clonal antibodies against cancers have been primarily generated
via hybridoma technology using B lymphocytes from cancer-
bearing patients (Yamaguchi et al, 1990; Posner et al, 1991; Hoon
et al, 1993; Oka et al, 1994). In spite of the existence of this
specific cancer recognition by the patient's immune system.
tumours do grow in aphysiological environment, implying that the
humoral response was an insufficient contribution to the anti-
tumour effect. The basic strategy of cancer biotherapy is to
magnify or to modify the innate anti-tumour immune system using
a variety of 'bioweapons' such as cytokines (Rosenberg et al.
1989; Weineretal, 1991; Dillman et al, 1993; Ernstoff 1994). gene
transfer (Porgador et al, 1993; Tohmatsu et al. 1993: Iwanuma et
al, 1995), adoptive transfer of activated killer cells (Rosenberg et
al, 1986; Andreesen et al, 1990; Keilholz et al. 1994) and cancer
vaccinations (Elliott et al. 1993; Hoover et al, 1993; Houghton.
1995). So far, the majority of these approaches have involved
cellular immunity, whereas human antibodies have been used in in
vivo diagnosis ofmalignancies only (Ditzel et al. 1993: Chaudhuri
et al, 1994; Ditzel et al, 1994).
The expected anti-tumour effects of human monoclonal anti-
bodies could be listed as follows: (1) to bind the functional mole-
cule in the metastasizing process of cancer cells, such as invasion.
destroying basal membrane, or implantation in distant organs.
thereby blocking the cancer metastases or expansions: (2) to
induce antibody-dependent cell-mediated cytotoxicity (ADCC) or
complement dependent cytolysis (CDC) against cancer cells: and
(3) to induce anti-idiotypic antibody against the administered
HuMAbs. This second antibody may mimic the tumour-associated
antigen(s) and offer an opportunity to induce a cell-mediated
immune response specific to tumour cells (Ferrone 1993:
Fargerberg et al. 1995).
The current data indicate that the antigen that is recognized by
HuMAb SKI is a two-chain molecule with approximate molecular
weight of 42-46 kDa, as it appears from the two most prominent
bands (Figure 2). Tissue specificity analysis showed that HuMAb
SKI preferentially stained adenocarcinoma tissues with minimal
to negative staining among non-epithelial tumours and normal
epithelium (Table 1). The antigen-positive cells within each colon
cancer cell line seemed to represent a discrete subset with different
levels of Ag expression, judging from FACS analysis (Figure 5)
and from the immunocytochemical staining of HT-29 (Figure 3).
There was a variety of Ag-positive ratios observed, depending
upon the harvested time of the cells (FACS data from Table 2).
Furthermnore, there were variations in antigen location and inten-
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Figure 7 Microscopic features of upper and lower sides of the membrane in the chemotaxis chamber. LoVo colon cancer cells migrated to the lower side of
the membrane after 36 h of incubatkin (left arrow). This cell migration was almost completely inhibited by the addition of HuMAb SK1 in the upper chamber
(right). Scale bars = 200 jm
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Figure 8 Dose-dependent inhibition of cell migration with HuMAb SK1
added in the upper chemotaxis chamber. The vertical line indicates a number
of migrated cells to the lower side of the membrane per 1 cells. The
horizontal line indicates concentration of antiodies. No inhbiton was
observed with irrelevant hurnan IgM MAb. Cell line used was LoVo colon
cancer cell line. *, SK1; IgM
sitv in Calu-l and PANC-1 cells (Figure 4). These data suggest
that the antigen is not always expressed on a given cell but is
possibly metabolized in each cell depending on the circumstances.
A dot-blot analysis and FACS analysis showed that the invasion
capacity of eight colon carcinoma cell lines correlates with the
Ag-SKI concentration of each cell line and with the ratio of
Ag-SK1-positive cells (Figure 6. Table 2). In addition. cell migra-
tion was inhibited by the addition of HuMAb SKI in a dose-
dependent manner. Taken together. these data suggest that HuMAb
SKl recognizes an antigen related to colon carcinoma cell inva-
sion that appears to be not only metabolized according, to physio-
logical circumstances but is also expressed on highly invasive cell
populations.
Although SKI did not cross-block with mouse monoclonal anti-
bodies directed to the known invasion- or metastasis-related mole-
cule such as E-cadherin. sialyl Tn. sialyl Le,. sialyl Lea. vitronectin
receptor alpha-chain. integrin beta 1- or beta 3-chains (data not
shown). the possibility that SKl recognizes an epitope that
contains some of these molecules still remains. as the mouse and
human MAb might recognize different epitopes on the same
molecule. This is an issue to be analvsed further.
In the current study. we evaluated 1036 HuMAbs derived from 18
regional lymph nodes of six Dukes' B colon cancerpatients. Among,
them. a high reaction specificity against cancer cefls was seen in
only one HuMAb. SKl. Although we used the lymphocytes derived
from the nearest lymphoid system to the tumour. the appearance
frequency of specific HuMAbs was unexpectedly small. suggesting
that most of the patients may not raise a humoral immune response
to autologous tumours. otherwise the B-cell population that is
primed to secrete a specific antibody to tumours is small in number
or is not fully activated to be fused (Koda et al. 1990).
The inhibition of in vitro colon cancer invasiveness by HuMAb
SKl required as much as ji, ml-' of antibody concentration
(Figure 8). which is unlikely to be secreted by such small cell
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populations of tumour-specific B lymphocytes in regional lymph
nodes. This suggests that human natural antibodies to carcinoma.
even when they exist. may not play an anti-cancer role effectively
under physiological conditions.
A HuMAb SKI is considered to be an augmentation of the
natural humoral immune response of cancer-bearing patients. It
may encourage successful cancer biotherapy using such HuMAbs
that exert a direct action upon cancer invasion and metastases.
Although the appearance of SKI was low in frequency (1 out of
1036). its existence does suggest that there may be others also
specific to cancer. The task then is to develop appropriate search
protocols to prove effectively the entire human immune response
repertoire and identify those sequences that identify cancer-
specific antigens.
The availability of immunoreagents such as SKI will not only
provide new insights into the working of the anti-cancer human
immune response but also give the oncologist clinically useful
antibodies for better diagnosis and therapy.
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